Global Senior Medical Director

Ipsen nominates Catherine Bradley to its Board of Directors as independent Director. By GlobeNewswire July 30, 2026 Ipsen appoints Catherine Bradley as independent Director to its Board of Directors PARIS, FRANCE, 29 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Catherine Bradley, CBE, as an independent Director to its Board of Directors, effective immediately. Ms. Bradley succeeds Ms. Witts who stepped down from the Board following the Annual General Meeting held on 13 May 2026. With more than 3 decades of experience in investment banking and international financial markets, followed by more than ten years of experience as a non-executive director, Ms. Bradley is a recognized expert in the financial sector and corporate governance. She has held senior leadership positions at leading global financial institutions including Merrill Lynch, Crédit Suisse and BNP Paribas. She also has specific experience in audit committee governance, having chaired the audit committees of the FCA (Financial Conduct Authority) and Aberdeen plc in the United Kingdom, Groupe Peugeot SA in France and Worldpay LLC in the United States. She currently serves as a non-executive director on several boards, notably as Chair of Interactive Investor Limited, as well as at Johnson Electric Holdings Limited in Asia, and easyJet plc, where she chairs the Finance Committee. Ms. Bradley is a graduate of HEC Paris, where she specialized in finance and international economics. Ms. Bradley is a Commander of the Order of the British Empire (CBE). The Board of Directors has also appointed Ms. Bradley as Chair of the Audit Committee and a member of the Compensation Committee. Her appointment will be submitted for ratification at the next Annual Shareholders' Meeting and, if ratified, will continue for the remainder of Ms. Witts' term of office, until the Annual Shareholders' Meeting to be held in 2029. Following this appointment, Ipsen's Board of Directors continues to comprise 14 directors, with equal representation of seven women1 and seven men. The Board includes four independent directors and two employee representatives. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com. | Ipsen Contacts Advertisement | / | / | | Investors | / | / | | Henry Wheeler | [email protected] | +33 7 66 47 11 49 | | Khalid Deojee | [email protected] | +33 6 66 01 95 26 | | Media | / | / | | Sally Bain | [email protected] | +1 857 320 0517 | | Anne Liontas | [email protected] | +33 7 67 34 72 96 | Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on ipsen.com. 1 Representing 42%, with directors representing employees not taken into account in this calculation, pursuant to article L. 225-18-1 of the French Code of Commerce

Ipsen's rare disease drug Bylvay (odevixibat) failed to meet its primary endpoint in a Phase III trial for biliary atresia, causing the company's stock to fall. The BOLD trial enrolled 254 patients across 19 countries who had undergone Kasai hepatoportoenterostomy surgery within their first 90 days of life. The study did not demonstrate improvement in native liver survival versus placebo. Biliary atresia, affecting one in 5,000-20,000 newborns, is the leading cause of paediatric liver transplant, with no approved medical treatments beyond surgery. Bylvay is approved in the US and EU for treating cholestatic pruritus in Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome. The drug generated €180 million for Ipsen in 2025, up 32.5% from the previous year.

The EU's first joint clinical assessment (JCA) has been published, evaluating Ipsen's Ojemda (tovorafenib) for paediatric low-grade glioma. The assessment took 399 days to complete under the EU's Health Technology Assessment Regulation. Whilst the JCA provides a technical template for future assessments, practical benefits remain unclear. The process aims to reduce duplication by creating harmonised clinical evidence for all 27 EU member states, but doesn't influence pricing. As of July 2026, only Germany has started an HTA and awarded reimbursement status. The Netherlands published a preliminary assessment recommending cost-containment measures pending negotiations. The JCA may accelerate pricing decisions in smaller EU states with less developed HTA capabilities, whilst countries with advanced HTA systems will likely see smaller benefits.